{"id":9453,"date":"2025-02-25T21:00:00","date_gmt":"2025-02-25T15:30:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9453"},"modified":"2025-02-25T17:59:55","modified_gmt":"2025-02-25T12:29:55","slug":"alzheimers-disease-market-trend","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend","title":{"rendered":"Alzheimer&#8217;s Disease: Navigating the Rising Incidence, Evolving Treatments, and Market Dynamics"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0de78fb776c\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0de78fb776c\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend\/#Rising_Incidence_of_Alzheimers_Disease\" >Rising Incidence of Alzheimer&#8217;s Disease<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend\/#Factors_Influencing_the_Rising_Incidence\" >Factors Influencing the Rising Incidence<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend\/#Economic_Impact_of_Alzheimers_Disease\" >Economic Impact of Alzheimer\u2019s Disease<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend\/#The_Link_Between_Menopause_and_Alzheimers_Disease\" >The Link Between Menopause and Alzheimer\u2019s Disease<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend\/#Psychosis_in_Parkinsons_Disease_Alzheimers_Disease\" >Psychosis in Parkinson\u2019s Disease &amp; Alzheimer\u2019s Disease<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend\/#Agitation_in_Alzheimers_Disease_A_Critical_Challenge\" >Agitation in Alzheimer\u2019s Disease: A Critical Challenge<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend\/#How_is_Alzheimers_Disease_Treated\" >How is Alzheimer\u2019s Disease Treated?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend\/#Approved_Therapies_in_the_Alzheimers_Disease_Treatment_Market\" >Approved Therapies in the Alzheimer\u2019s Disease Treatment Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend\/#Recent_Advancements_in_the_Alzheimers_Disease_Therapies_Landscape\" >Recent Advancements in the Alzheimer\u2019s Disease Therapies Landscape<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend\/#Promising_Therapies_in_the_Alzheimers_Disease_Pipeline\" >Promising Therapies in the Alzheimer\u2019s Disease Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend\/#Could_a_Diabetes_Drug_Help_Prevent_Alzheimers\" >Could a Diabetes Drug Help Prevent Alzheimer\u2019s?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend\/#Future_Outlook_for_Alzheimers_Disease_Treatment\" >Future Outlook for Alzheimer&#8217;s Disease Treatment<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Alzheimer\u2019s disease is more than just memory loss\u2014<strong><em>it\u2019s a progressive neurodegenerative disorder <\/em><\/strong>that slowly erodes cognition, behavior, and independence. What may begin as occasional forgetfulness or difficulty recalling names can soon escalate into disorientation, personality changes, and an inability to carry out daily tasks. As the disease advances, patients lose their connection to the world around them, making early detection and intervention crucial.<\/p>\n\n\n\n<p>Recognizing <strong>Alzheimer\u2019s symptoms<\/strong> early can help in diagnosis and care planning. Physicians use cognitive tests, brain imaging (PET scans, MRIs), and biomarker analysis of cerebrospinal fluid or blood to confirm an Alzheimer\u2019s diagnosis. These diagnostic advancements have paved the way for more precise and timely interventions, allowing patients to access the latest treatment options sooner.&nbsp;<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-diagnostic-market\">Alzheimer\u2019s Disease Diagnostic Market<\/a> is primarily driven by advancements in diagnostic technologies such as brain imaging, genetic testing, and blood-based tests. Among these, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/computed-tomography-market\">computed tomography<\/a> segment is expected to hold a significant market share due to its ability to detect brain mass loss and differentiate Alzheimer\u2019s from other types of dementia. The increasing launch of CT technologies, such as <strong>Philips&#8217; Spectral CT 7500,<\/strong> is further boosting market demand. A rising geriatric population, increasing traumatic brain injuries, and higher Alzheimer\u2019s prevalence are driving North America&#8217;s dominance in the AD diagnostic market. These factors are fueling market growth, making the region a promising hub for Alzheimer\u2019s diagnostics.<\/p>\n\n\n\n<p>For years, doctors treated Alzheimer\u2019s disease with cholinesterase inhibitors and NMDA receptor antagonists, which provided temporary relief but failed to slow disease progression. However, a revolutionary shift is underway. Recent FDA-approved <strong>Alzheimer\u2019s treatment drugs<\/strong>, including monoclonal antibodies like LEQEMBI and KISUNLA, target amyloid plaques\u2014the root cause of neurodegeneration\u2014offering hope of slowing cognitive decline. With emerging therapies exploring tau protein aggregation, neuroinflammation, and gene-based approaches, the fight against Alzheimer\u2019s is entering a new era\u2014one where stopping the disease may no longer be an impossible dream.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-rising-incidence-of-alzheimer-s-disease\"><span class=\"ez-toc-section\" id=\"Rising_Incidence_of_Alzheimers_Disease\"><\/span>Rising Incidence of Alzheimer&#8217;s Disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Alzheimer\u2019s disease is a mounting public health challenge, with its incidence rising at an alarming rate worldwide. Currently, an estimated <strong>50 million people<\/strong> are living with Alzheimer&#8217;s, and projections indicate that this number will skyrocket to <strong>75 million by 2030<\/strong> and <strong>131.5 million by 2050<\/strong>, according to Alzheimer\u2019s Disease International. In the <strong>seven major markets (7MM)<\/strong>, nearly <strong>16 million diagnosed prevalent cases<\/strong> were reported in 2023, with the United States alone accounting for <strong>6.9 million cases<\/strong>. Notably, Alzheimer&#8217;s disproportionately affects women, with <strong>4.6 million<\/strong> cases among females compared to <strong>2.3 million in men<\/strong>. Age remains a critical risk factor, with individuals aged <strong>75\u201384 years<\/strong> making up approximately <strong>44% of the diagnosed cases in the 7MM<\/strong>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"394\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12122806\/Alzheimers-Disease-Epidemiology-Insights-2023-1024x394.png\" alt=\"Alzheimer's-Epidemiology-Insights\" class=\"wp-image-31001\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12122806\/Alzheimers-Disease-Epidemiology-Insights-2023-1024x394.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12122806\/Alzheimers-Disease-Epidemiology-Insights-2023-300x115.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12122806\/Alzheimers-Disease-Epidemiology-Insights-2023-150x58.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12122806\/Alzheimers-Disease-Epidemiology-Insights-2023-768x295.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12122806\/Alzheimers-Disease-Epidemiology-Insights-2023-1536x591.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12122806\/Alzheimers-Disease-Epidemiology-Insights-2023-2048x788.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-factors-influencing-the-rising-incidence\"><span class=\"ez-toc-section\" id=\"Factors_Influencing_the_Rising_Incidence\"><\/span>Factors Influencing the Rising Incidence<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Several factors contribute to the rising <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-epidemiology-forecast\">incidence of Alzheimer\u2019s disease,<\/a> including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Aging Population:<\/strong> With increasing life expectancy, the number of individuals at risk is growing.<\/li>\n\n\n\n<li><strong>Genetics &amp; Family History:<\/strong> People with a family history of Alzheimer&#8217;s have a higher likelihood of developing the disease.<\/li>\n\n\n\n<li><strong>Lifestyle &amp; Environmental Factors:<\/strong> Poor cardiovascular health, sedentary lifestyles, and diets high in processed foods may contribute to cognitive decline.<\/li>\n\n\n\n<li><strong>Comorbidities:<\/strong> Conditions such as diabetes, hypertension, and obesity are linked to an increased risk of Alzheimer&#8217;s.<\/li>\n\n\n\n<li><strong>Hormonal Changes:<\/strong> Emerging research suggests a potential connection between <strong>menopause and Alzheimer\u2019s disease<\/strong>, further increasing the disease burden among women.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-economic-impact-of-alzheimer-s-disease\"><span class=\"ez-toc-section\" id=\"Economic_Impact_of_Alzheimers_Disease\"><\/span>Economic Impact of Alzheimer\u2019s Disease<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Alzheimer\u2019s disease not only affects individuals and families but also places a significant burden on healthcare systems and economies. The cost of Alzheimer\u2019s care includes:<\/p>\n\n\n\n<p><strong>Direct Costs:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Long-term <strong>skilled nursing care<\/strong>, home healthcare, and hospice services<\/li>\n\n\n\n<li><strong>Medication therapy management<\/strong> for symptom relief and disease-modifying treatments<\/li>\n<\/ul>\n\n\n\n<p><strong>Indirect Costs:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Loss of productivity<\/strong> for patients and caregivers<\/li>\n\n\n\n<li><strong>Reduced quality of life<\/strong> due to behavioral and cognitive decline<\/li>\n\n\n\n<li><strong>Informal caregiving burdens<\/strong>, often leading to emotional and financial stress for families<\/li>\n<\/ul>\n\n\n\n<p>According to the <strong>National Library of Medicine<\/strong>, Alzheimer\u2019s treatment costs were estimated at <strong>$305 billion in 2020<\/strong>, with projections surpassing <strong>$1 trillion by 2050<\/strong>\u2014a staggering financial challenge for global healthcare systems.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-the-link-between-menopause-and-alzheimer-s-disease\"><span class=\"ez-toc-section\" id=\"The_Link_Between_Menopause_and_Alzheimers_Disease\"><\/span>The Link Between Menopause and Alzheimer\u2019s Disease<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>An important discovery in Alzheimer\u2019s research is the <strong>link between menopause and cognitive decline<\/strong>. Menopause, which typically occurs between <strong>ages 45 and 55<\/strong>, leads to a drastic reduction in <strong>estrogen and progesterone levels<\/strong>\u2014hormones that play a crucial role in brain function. Scientists believe this hormonal shift may <strong>increase women\u2019s vulnerability to Alzheimer\u2019s disease<\/strong>, making it a critical area of study.<\/p>\n\n\n\n<p><strong><em>Read our latest blog to explore the connection between <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/possible-link-between-alzheimers-and-menopause\"><strong><em>menopause and Alzheimer\u2019s disease<\/em><\/strong><\/a><strong><em>.<\/em><\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-psychosis-in-parkinson-s-disease-amp-alzheimer-s-disease\"><span class=\"ez-toc-section\" id=\"Psychosis_in_Parkinsons_Disease_Alzheimers_Disease\"><\/span>Psychosis in Parkinson\u2019s Disease &amp; Alzheimer\u2019s Disease<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/psychosis-in-parkinsons-and-alzheimers-disease-epidemiology-forecast\"><strong>Psychosis in neurodegenerative disorders<\/strong><\/a> manifests as hallucinations, delusions, and altered perceptions, significantly impacting quality of life. In <strong>Parkinson\u2019s disease<\/strong>, psychosis can stem from disease progression or medication side effects, whereas in <strong>Alzheimer\u2019s disease<\/strong>, it is more commonly associated with <strong>cognitive decline<\/strong>. Diagnosis relies on clinical evaluations, often informed by <strong>caregiver observations<\/strong>, highlighting the importance of early detection and intervention.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-agitation-in-alzheimer-s-disease-a-critical-challenge\"><span class=\"ez-toc-section\" id=\"Agitation_in_Alzheimers_Disease_A_Critical_Challenge\"><\/span>Agitation in Alzheimer\u2019s Disease: A Critical Challenge<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/agitation-in-alzheimer-disease\">Agitation<\/a> is a <strong>common and distressing symptom<\/strong> of Alzheimer\u2019s disease, characterized by <strong>restlessness, aggression, pacing, or verbal outbursts<\/strong>. It often worsens as the disease progresses, affecting both patients and caregivers.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biological Factors:<\/strong> Neurotransmitter imbalances, brain structural changes, and neuroinflammation contribute to behavioral disturbances.<\/li>\n\n\n\n<li><strong>Psychological &amp; Environmental Triggers:<\/strong> Fear, confusion, sleep disturbances, pain, and medication side effects can exacerbate agitation.<\/li>\n\n\n\n<li><strong>Caregiver Burden:<\/strong> Family members and healthcare professionals often struggle to manage these symptoms, necessitating comprehensive care strategies.<\/li>\n<\/ul>\n\n\n\n<p>Alzheimer\u2019s disease remains a <strong>pressing global challenge<\/strong>, demanding continuous innovation in <strong>treatment, early diagnosis, and patient care<\/strong>. Understanding its economic burden, hormonal links, and behavioral manifestations is essential to shaping <strong>better healthcare strategies and therapeutic advancements<\/strong>.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-is-alzheimer-s-disease-treated\"><span class=\"ez-toc-section\" id=\"How_is_Alzheimers_Disease_Treated\"><\/span>How is Alzheimer\u2019s Disease Treated?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Currently, available therapies for Alzheimer\u2019s disease primarily focus on symptom management by modulating key neurotransmitters such as acetylcholine, serotonin, and noradrenaline while aiming to reduce the activity of glutamate and dopamine. However, these approaches often come with side effects, emphasizing the need for personalized treatment strategies tailored to patient comorbidities and drug interactions. Recent approvals like <strong>LEQEMBI (lecanemab) by Biogen and Eisai<\/strong>, <strong>KISUNLA (donanemab-azbt) by Eli Lilly<\/strong>, and <strong>Brexpiprazole (REXULTI)<\/strong> reflect a shift toward more targeted therapeutic options in the <strong>Alzheimer\u2019s disease therapeutics market<\/strong>.<\/p>\n\n\n\n<p>Doctors have prescribed acetylcholinesterase inhibitors (AChEIs) and the NMDA receptor antagonist memantine in the U.S. and worldwide for over a decade. The <strong>FDA and EMA have approved three AChEIs<\/strong>\u2014<strong>donepezil, rivastigmine, and galantamine<\/strong>\u2014administered in over 60 countries for various stages of Alzheimer\u2019s disease. While these drugs provide <strong>modest symptomatic relief<\/strong>, their effects are temporary, requiring regular re-evaluation.<\/p>\n\n\n\n<p>Despite these treatments, challenges remain. The <strong>progressive nature of Alzheimer\u2019s disease<\/strong>, its <strong>uncertain pathology<\/strong>, and <strong>high treatment costs<\/strong> continue to hinder therapeutic advancements. Additionally, the <strong>benefit-risk ratio of these medications<\/strong> has led to varied reimbursement policies in countries like France.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-approved-therapies-in-the-alzheimer-s-disease-treatment-market\"><span class=\"ez-toc-section\" id=\"Approved_Therapies_in_the_Alzheimers_Disease_Treatment_Market\"><\/span>Approved Therapies in the Alzheimer\u2019s Disease Treatment Market<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\"><strong>Alzheimer\u2019s disease treatment market<\/strong><\/a> includes both FDA-approved therapies and off-label treatments that play a crucial role in managing the disease. Among the most notable therapies is <a href=\"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment\"><strong>LEQEMBI (lecanemab)<\/strong><\/a>, developed by <strong>Biogen Inc. and Eisai Co., Ltd.<\/strong>, which received FDA approval on <strong>January 6, 2023<\/strong>. LEQEMBI is a <strong>humanized IgG1 monoclonal antibody<\/strong> designed to reduce both soluble and insoluble amyloid beta (A\u00df) deposits, thereby slowing disease progression. In a significant development, the FDA approved its <strong>once-monthly maintenance dosing<\/strong> on <strong>January 26, 2025<\/strong>, offering a more convenient option compared to biweekly administration. Additionally, Eisai\u2019s <strong>subcutaneous autoinjector version<\/strong> is currently under FDA review, with a <strong>PDUFA action date set for August 31, 2025<\/strong>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"236\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-1024x236.png\" alt=\"Alzheimer's-Market-Insights\" class=\"wp-image-31026\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-1024x236.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-300x69.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-150x35.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-768x177.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-1536x353.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-2048x471.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><strong>Eli Lilly <\/strong>developed <strong>KISUNLA (donanemab-azbt)<\/strong>, which <strong>Japan <\/strong>approved in <strong>September 2024.<\/strong> This intravenous infusion (350 mg\/20 mL) treats patients with <strong>early symptomatic Alzheimer\u2019s disease<\/strong> every four weeks. This approval represents a significant advancement in global treatment accessibility, offering another targeted approach to managing the disease.<\/p>\n\n\n\n<p><strong>Brexpiprazole (REXULTI)<\/strong> has also emerged as an important adjunctive therapy in the treatment landscape. While not directly addressing the neurodegenerative aspects of Alzheimer\u2019s, it is widely used to manage <strong>neuropsychiatric symptoms<\/strong> such as agitation, depression, and psychosis, which are commonly observed in patients with moderate to severe Alzheimer\u2019s disease.<\/p>\n\n\n\n<p>These treatments significantly contribute to the <strong>Alzheimer\u2019s disease treatment market<\/strong>, which reached <strong>USD 3.6 billion in the 7MM in 2023<\/strong>. With several <strong>emerging therapies expected to launch between 2024 and 2034<\/strong>, the market is projected to experience substantial growth, driven by <strong>innovations in disease-modifying treatments and advancements in precision medicine<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-recent-advancements-in-the-alzheimer-s-disease-therapies-landscape\"><span class=\"ez-toc-section\" id=\"Recent_Advancements_in_the_Alzheimers_Disease_Therapies_Landscape\"><\/span>Recent Advancements in the Alzheimer\u2019s Disease Therapies Landscape<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline\"><strong>Alzheimer\u2019s disease drugs market<\/strong><\/a> is witnessing research and drug development breakthroughs. Several therapies and diagnostic innovations have recently gained regulatory recognition:<\/p>\n\n\n\n<p>Recently, the <strong>FDA granted Fast Track designation<\/strong> to <strong>troculeucel<\/strong> (Feb 12, 2025), an investigational <strong>NK cell therapy<\/strong> by NKGen Biotech, designed to address <strong>moderate Alzheimer\u2019s disease<\/strong>. This regulatory recognition aims to accelerate the development of therapies that target the disease\u2019s complex pathology. Additionally, on <strong>Jan 26, 2025<\/strong>, Eisai and Biogen received <strong>FDA approval for LEQEMBI\u2019s once-monthly maintenance dosing<\/strong>, offering a more convenient treatment option for patients in the <strong>Alzheimer\u2019s disease treatment market<\/strong>.&nbsp;<\/p>\n\n\n\n<p>Earlier in the month, on <strong>Jan 15, 2025<\/strong>, the FDA granted <strong>Breakthrough Device Designation<\/strong> to <strong>Spear Bio\u2019s pTau 217 blood test<\/strong>, marking a major step forward in <strong>Alzheimer\u2019s disease diagnosis<\/strong> by providing a <strong>less invasive<\/strong> alternative to PET scans and lumbar punctures. Furthermore, BioArctic\u2019s <strong>LEQEMBI subcutaneous autoinjector<\/strong> is set for an <strong>FDA decision by August 31, 2025<\/strong>, potentially expanding patient access to <strong>Alzheimer\u2019s disease medicines<\/strong> with a more user-friendly administration method.<\/p>\n\n\n\n<p>These groundbreaking advancements signal a transformative shift toward <strong>precision medicine in the Alzheimer\u2019s disease therapeutics market<\/strong>, enhancing both treatment accessibility and effectiveness. With the landscape evolving rapidly, staying informed is crucial.&nbsp;<\/p>\n\n\n\n<p>We&#8217;ve curated an exclusive blog covering the latest <strong>commercial activities, regulatory updates, and market trends in Alzheimer\u2019s treatment<\/strong>\u2014don\u2019t miss out on these critical insights! <strong>Read now and stay ahead of the curve.<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-promising-therapies-in-the-alzheimer-s-disease-pipeline\"><span class=\"ez-toc-section\" id=\"Promising_Therapies_in_the_Alzheimers_Disease_Pipeline\"><\/span>Promising Therapies in the Alzheimer\u2019s Disease Pipeline<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-pipeline-insight\"><strong>Alzheimer\u2019s disease treatment market<\/strong><\/a> is set for transformation, with several late-stage investigational drugs showing promising results in the Alzheimer\u2019s disease pipeline:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Masitinib (AB1010) \u2013 AB Science<\/strong>\n<ul class=\"wp-block-list\">\n<li>An <strong>orally administered tyrosine kinase inhibitor<\/strong> targeting <strong>neuro-immune cells (mast cells &amp; microglia)<\/strong> involved in Alzheimer\u2019s pathology.<\/li>\n\n\n\n<li><strong>Phase IIb\/III trials<\/strong> have demonstrated its ability to <strong>slow cognitive decline<\/strong>, and a <strong>confirmatory Phase III trial is underway<\/strong>.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Valiltramiprosate (ALZ-801) \u2013 Alzheon, Inc.<\/strong>\n<ul class=\"wp-block-list\">\n<li>A <strong>small-molecule prodrug<\/strong> designed to <strong>block neurotoxic amyloid oligomer formation<\/strong>.<\/li>\n\n\n\n<li>Currently in <strong>Phase III trials<\/strong>, showing <strong>improved gastrointestinal tolerance and stable plasma levels<\/strong> compared to its predecessor, tramiprosate.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Tricaprilin (CER-0001) \u2013 Cerecin<\/strong>\n<ul class=\"wp-block-list\">\n<li>A <strong>ketogenic agent<\/strong> designed to provide an alternative <strong>energy source to neurons<\/strong> by inducing mild ketosis.<\/li>\n\n\n\n<li>Aims to <strong>counteract declining glucose metabolism<\/strong> in Alzheimer\u2019s patients.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Remternetug (LY3372993) \u2013 Eli Lilly<\/strong>\n<ul class=\"wp-block-list\">\n<li>Researchers expect a late-stage <strong>Phase III monoclonal antibody<\/strong> therapy targeting pyroglutamated amyloid-beta to conclude trials by <strong>October 2025.<\/strong><\/li>\n\n\n\n<li>If successful, it could become <strong>one of the most effective Alzheimer\u2019s disease drugs<\/strong> available, further reinforcing its potential in the <strong>Alzheimer\u2019s disease therapeutics market<\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<p>As multiple late-stage therapies near approval, the<strong> Alzheimer\u2019s disease drugs market <\/strong>advances significantly. Companies like <strong>AB Science, Alzheon, AriBio, AgeneBio, Anavex Life Sciences Corp., Cassava Sciences, Novo Nordisk, Eisai, and others<\/strong> are leading research efforts with promising <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-pipeline-insight\"><strong>Alzheimer\u2019s disease therapies<\/strong><\/a>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"218\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133448\/Key-Players-Working-in-the-Alzheimers-Disease-Treatment-Market-1024x218.png\" alt=\"Key-Players-Working-in-the-Alzheimer's-Disease-Treatment-Market\" class=\"wp-image-31027\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133448\/Key-Players-Working-in-the-Alzheimers-Disease-Treatment-Market-1024x218.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133448\/Key-Players-Working-in-the-Alzheimers-Disease-Treatment-Market-300x64.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133448\/Key-Players-Working-in-the-Alzheimers-Disease-Treatment-Market-150x32.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133448\/Key-Players-Working-in-the-Alzheimers-Disease-Treatment-Market-768x163.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133448\/Key-Players-Working-in-the-Alzheimers-Disease-Treatment-Market-1536x326.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133448\/Key-Players-Working-in-the-Alzheimers-Disease-Treatment-Market-2048x435.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<p><em>Could <\/em><strong><em>Remternetug or other late-stage therapies<\/em><\/strong><em> be the breakthrough the world has been waiting for? <\/em><a href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market\"><strong><em>Read more about the latest developments here!<\/em><\/strong><\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-could-a-diabetes-drug-help-prevent-alzheimer-s\"><span class=\"ez-toc-section\" id=\"Could_a_Diabetes_Drug_Help_Prevent_Alzheimers\"><\/span><strong>Could a Diabetes Drug Help Prevent Alzheimer\u2019s?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Originally developed for <strong>type 2 diabetes and weight loss<\/strong>, semaglutide is now gaining attention for its <strong>potential to reduce Alzheimer\u2019s disease risk<\/strong>. Research suggests it may <strong>protect brain health<\/strong> by improving <strong>insulin sensitivity, reducing neuroinflammation, and enhancing brain metabolism<\/strong>.<\/p>\n\n\n\n<p>A recent study published in Alzheimer\u2019s &amp; Dementia found that semaglutide users had a <strong>78% lower risk of developing Alzheimer\u2019s<\/strong> compared to those on other diabetes medications. With Novo Nordisk\u2019s <strong>EVOKE and EVOKE+ trials<\/strong> underway, scientists are now investigating whether semaglutide could <strong>slow or prevent cognitive decline<\/strong> in non-diabetic individuals.<\/p>\n\n\n\n<p><strong><em>Could semaglutide redefine Alzheimer\u2019s prevention? <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/semaglutide-for-alzheimers-disease-treatment\"><strong><em>Read more<\/em><\/strong><\/a><strong><em> about the emerging connection between diabetes and neurodegeneration today!<\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-future-outlook-for-alzheimer-s-disease-treatment\"><span class=\"ez-toc-section\" id=\"Future_Outlook_for_Alzheimers_Disease_Treatment\"><\/span>Future Outlook for Alzheimer&#8217;s Disease Treatment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Alzheimer\u2019s disease remains one of the most complex and pressing healthcare challenges of our time. With its rising global incidence, significant economic burden, and devastating impact on patients and caregivers, the demand for effective treatments and preventive strategies has never been greater. For decades, the treatment landscape was limited to symptom management, but the emergence of disease-modifying therapies\u2014such as <strong>monoclonal antibodies targeting amyloid plaques\u2014marks a turning point in the fight against neurodegeneration.<\/strong><\/p>\n\n\n\n<p>Yet, the pursuit of a cure continues. New research into tau-targeting drugs, neuroinflammation, and gene-based therapies is expanding our understanding of Alzheimer\u2019s pathology, while innovative diagnostic tools, such as blood-based biomarkers, are paving the way for earlier and more accurate detection. Meanwhile, unexpected breakthroughs\u2014such as the potential neuroprotective effects of semaglutide, originally developed for diabetes\u2014suggest that <strong><em>Alzheimer\u2019s treatment may also come from unlikely sources<\/em><\/strong>, redefining how we approach prevention and care.<\/p>\n\n\n\n<p>As pharmaceutical companies push forward with late-stage clinical trials and regulatory bodies accelerate drug approvals, hope is on the horizon. The Alzheimer\u2019s disease therapeutic landscape is at a pivotal moment, where scientific advancements and therapeutic innovations may soon change the trajectory of this condition. The future of Alzheimer\u2019s care is no longer just about managing decline\u2014it\u2019s about slowing, stopping, and ultimately preventing it.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-1024x194.png\" alt=\"Alzheimer's Disease Market Outlook\" class=\"wp-image-31013\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Alzheimer\u2019s disease is more than just memory loss\u2014it\u2019s a progressive neurodegenerative disorder that slowly erodes cognition, behavior, and independence. What may begin as occasional forgetfulness or difficulty recalling names can soon escalate into disorientation, personality changes, and an inability to carry out daily tasks. As the disease advances, patients lose their connection to the world [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":31133,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[2314,18396,18050,1856,7145,6641,18402,18394,18395,18399,18400,18397,1135,17897,423,1736,18398,18401],"industry":[17225],"therapeutic_areas":[17229,17245],"class_list":["post-9453","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-ac-immune","tag-agenebio","tag-alkahest","tag-alzheimers","tag-alzheimers-disease-market","tag-alzheimers-disease-therapies","tag-alzheimeras-disease","tag-alzheimers-disease-market-scenario","tag-amarantus-bioscience-holdings","tag-az-therapies","tag-cerecin","tag-cortexyme","tag-genentech","tag-neurotrope-bioscience","tag-novartis","tag-otsuka-pharmaceutical","tag-taurx-therapeutics","tag-vtv-therapeutics","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Alzheimer\u2019s Disease Market Trends, Therapies, and Future Outlook<\/title>\n<meta name=\"description\" content=\"Discover Alzheimer\u2019s disease market trends, breakthrough therapies, and future treatment innovations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alzheimer\u2019s Disease Market Trends, Therapies, and Future Outlook\" \/>\n<meta property=\"og:description\" content=\"Discover Alzheimer\u2019s disease market trends, breakthrough therapies, and future treatment innovations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-25T15:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/25175757\/Alzheimers-disease-f8.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alzheimer\u2019s Disease Market Trends, Therapies, and Future Outlook","description":"Discover Alzheimer\u2019s disease market trends, breakthrough therapies, and future treatment innovations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend","og_locale":"en_US","og_type":"article","og_title":"Alzheimer\u2019s Disease Market Trends, Therapies, and Future Outlook","og_description":"Discover Alzheimer\u2019s disease market trends, breakthrough therapies, and future treatment innovations.","og_url":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-02-25T15:30:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/25175757\/Alzheimers-disease-f8.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend","url":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend","name":"Alzheimer\u2019s Disease Market Trends, Therapies, and Future Outlook","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/25175757\/Alzheimers-disease-f8.png","datePublished":"2025-02-25T15:30:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Discover Alzheimer\u2019s disease market trends, breakthrough therapies, and future treatment innovations.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/25175757\/Alzheimers-disease-f8.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/25175757\/Alzheimers-disease-f8.png","width":466,"height":284,"caption":"Alzheimer's Disease: Navigating the Rising Incidence, Evolving Treatments, and Market Dynamics"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/25175757\/Alzheimers-disease-f8-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">AC Immune<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Agenebio<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alkahest<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">alzheimer&#039;s<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer&#039;s Disease Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer&#039;s disease therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer\u00e2\u0080\u0099s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer\u0092s Disease Market Scenario<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Amarantus Bioscience Holdings<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">AZ Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cerecin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cortexyme<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Genentech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Neurotrope Bioscience<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Otsuka Pharmaceutical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Taurx Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Vtv Therapeutics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AC Immune<\/span>","<span class=\"advgb-post-tax-term\">Agenebio<\/span>","<span class=\"advgb-post-tax-term\">Alkahest<\/span>","<span class=\"advgb-post-tax-term\">alzheimer&#039;s<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer&#039;s Disease Market<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer&#039;s disease therapies<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer\u00e2\u0080\u0099s disease<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer\u0092s Disease Market Scenario<\/span>","<span class=\"advgb-post-tax-term\">Amarantus Bioscience Holdings<\/span>","<span class=\"advgb-post-tax-term\">AZ Therapies<\/span>","<span class=\"advgb-post-tax-term\">Cerecin<\/span>","<span class=\"advgb-post-tax-term\">Cortexyme<\/span>","<span class=\"advgb-post-tax-term\">Genentech<\/span>","<span class=\"advgb-post-tax-term\">Neurotrope Bioscience<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Otsuka Pharmaceutical<\/span>","<span class=\"advgb-post-tax-term\">Taurx Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Vtv Therapeutics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Feb 25, 2025","modified":"Updated on Feb 25, 2025"},"absolute_dates_time":{"created":"Posted on Feb 25, 2025 9:00 pm","modified":"Updated on Feb 25, 2025 5:59 pm"},"featured_img_caption":"Alzheimer's Disease: Navigating the Rising Incidence, Evolving Treatments, and Market Dynamics\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9453","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9453"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9453\/revisions"}],"predecessor-version":[{"id":31134,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9453\/revisions\/31134"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/31133"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9453"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9453"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9453"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9453"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9453"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}